top of page
  • Recruiting

NCT05113342: Phase 1/2: Descartes-25 in Relapsed/Refractory Multiple Myeloma

Updated: Jun 22, 2022

NCT05113342: Phase 1/2: Descartes-25 in Relapsed/Refractory Multiple Myeloma


descartes 25 cartesian therapeutics

Descartes-25 in Relapsed/Refractory Multiple Myeloma


This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with Relapsed/Refractory Multiple Myeloma.


Sponsor

 

ClinicalTrials.gov Identifier: NCT05113342


Official Title: Phase I/IIa Study of Descartes-25 in Patients With Relapsed/Refractory Multiple Myeloma


First Posted: November 9, 2021


Click here to see details on ClinicalTrials.gov

 

Drug: Descartes-25

 

Locations:


United States, Maryland

Center for Cancer and Blood Disorders

Bethesda, Maryland, United States, 20817


United States, Wisconsin

Medical College of Wisconsin

Madison, Wisconsin, United States, 53226







Comments


Posts Archive
bottom of page